Literature DB >> 15063362

Anti-inflammatory therapy for heart failure.

Akira Matsumori1.   

Abstract

Recently, inflammation has been shown to be an important aspect of cardiovascular diseases, and markers of inflammation predict risk of adverse cardiovascular events. Accumulating evidence shows that heart failure is an inflammatory disease, and anti-inflammatory therapy by various agents would be a promising future treatment for heart failure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15063362     DOI: 10.1016/j.coph.2003.11.003

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  5 in total

1.  Effects of telmisartan on markers of ventricular remodeling in patients with acute myocardial infarction: comparison with enalapril.

Authors:  Takashi Yokota; Tomohiro Osanai; Kenji Hanada; Motoi Kushibiki; Naoki Abe; Koichi Oikawa; Hirofumi Tomita; Takumi Higuma; Jin Yokoyama; Hiroyuki Hanada; Ken Okumura
Journal:  Heart Vessels       Date:  2010-10-05       Impact factor: 2.037

2.  Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community.

Authors:  Arduino A Mangoni; Richard J Woodman; Paraskevi Gaganis; Andrew L Gilbert; Kathleen M Knights
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

Review 3.  Platelet activating factor in heart failure: potential role in disease progression and novel target for therapy.

Authors:  Paraskevi Detopoulou; Tzortzis Nomikos; Elizabeth Fragopoulou; Christina Chrysohoou; Smaragdi Antonopoulou
Journal:  Curr Heart Fail Rep       Date:  2013-06

4.  Efficacy and safety of electroacupuncture in acute decompensated heart failure: a study protocol for a randomized, patient- and assessor-blinded, sham controlled trial.

Authors:  Jungtae Leem; Seung Min Kathy Lee; Jun Hyeong Park; Suji Lee; Hyemoon Chung; Jung Myung Lee; Weon Kim; Sanghoon Lee; Jong Shin Woo
Journal:  BMC Complement Altern Med       Date:  2017-07-11       Impact factor: 3.659

5.  Chronic intermittent hypobaric hypoxia attenuates monocrotaline-induced pulmonary arterial hypertension via modulating inflammation and suppressing NF-κB/p38 pathway.

Authors:  Lei Gao; Jun Liu; Yongmei Hao; Zengren Zhao; Huilian Tan; Jie Zhang; Ning Meng; Qinghou Zheng; Zhen Wang; Yi Zhang
Journal:  Iran J Basic Med Sci       Date:  2018-03       Impact factor: 2.699

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.